Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 de Weers M, Mensink RG, Kraakman ME, Schuurman RK, Hendriks RW. Mutation analysis of the Bruton's tyrosine kinase gene in X-linked agammaglobulinemia: identification of a mutation which affects the same codon as is altered in immunodeficient xid mice. Hum. Mol. Genet. 3(1), 161–166 (1994).
  Medline CASGoogle Scholar
• 2 Herman SE, Gordon AL, Hertlein E et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood 117(23), 6287–6296 (2011).
  Medline CASGoogle Scholar
• 3 Byrd JC, Furman RR, Coutre SE et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N. Engl. J. Med. 369(1), 32–42 (2013). •• The most definitive published results of ibrutinib in relapsed chronic lymphocytic leukemia.
  Medline CASGoogle Scholar
• 4 Wang ML, Rule S, Martin P et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N. Engl. J. Med. 369(6), 507–516 (2013). •• The most definitive published results of ibrutinib in relapsed mantle cell lymphoma.
  Medline CASGoogle Scholar
• 5 Hallek M, Fischer K, Fingerle-Rowson G et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, Phase 3 trial. Lancet 376(9747), 1164–1174 (2010).
  Medline CASGoogle Scholar
• 6 Fischer K, Cramer P, Busch R et al. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter Phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J. Clin. Oncol. 30(26), 3209–3216 (2012).
  Medline CASGoogle Scholar
• 7 Eichhorst B, Fink AM, Busch RB et al. Chemoimmunotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) versus bendamustine and rituximab (BR) in previously untreated and physically fit patients (pts) with advanced chronic lymphocytic leukemia (CLL): results of a planned interim analysis of the CLL10 trial, an international, randomized study of The German CLL Study Group (GCLLSG). Presented at: The 55th ASH® Annual Meeting and Exposition. LA, USA, 7–10 December 2013.
  Google Scholar
• 8 Rummel MJ, Niederle N, Maschmeyer G et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, Phase 3 non-inferiority trial. Lancet 381(9873), 1203–1210 (2013).
  Medline CASGoogle Scholar
• 9 Goede V, Fischer K, Busch R et al. Head-to-head comparison of obinutuzumab (GA101) plus chlorambucil (Clb) versus rituximab plus clb in patients with chronic lymphocytic leukemia (CLL) and co-existing medical conditions (comorbidities): final stage 2 results of the CLL11 trial. Presented at: The 55th ASH® Annual Meeting and Exposition. LA, USA, 7–10 December 2013. 
  Google Scholar
• 10 Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365(8), 725–733 (2011).
  Medline CASGoogle Scholar
• 11 Honigberg LA, Smith AM, Sirisawad M et al. The bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc. Natl Acad. Sci. USA 107(29), 13075–13080 (2010).  • Important preclinical work that provided the rationale for exploring ibrutinib in the clinic.
  Medline CASGoogle Scholar
• 12 Dubovsky JA, Beckwith KA, Natarajan G et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood 122(15), 2539–2549 (2013).
  Medline CASGoogle Scholar
• 13 Advani RH, Buggy JJ, Sharman JP et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J. Clin. Oncol. 31(1), 88–94 (2013). • Final results of the Phase I study of ibrutinib in relapsed/refractory B-cell malignancies.
  Medline CASGoogle Scholar
• 14 Ponader S, Chen SS, Buggy JJ et al. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood 119(5), 1182–1189 (2012). 
  Medline CASGoogle Scholar
• 15 O'Brien S, Furman RR, Coutre SE et al. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, Phase 1b/2 trial. Lancet Oncol. 15(1), 48–58 (2013). •• Most definitive published results of ibrutinib in previously untreated chronic lymphocytic leukemia.
  MedlineGoogle Scholar
• 16 Wilson WH, Gerecitano JF, Goy A et al. The Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), has preferential activity in the ABC subtype of relapsed/refractory de novo diffuse large B-Cell lymphoma (DLBCL): interim results of a multicenter, open-label, Phase 2 study. Presented at: The 55 ASH® Annual Meeting and Exopsition. LA, USA, 7–10 December 2013 (Abstract 686).
  Google Scholar
• 17 Treon SP, Tripsas CK, Yang, G et al. A prospective multicenter study of the bruton's tyrosine kinase inhibitor ibrutinib in patients with relapsed or refractory waldenstrom's macroglobulinemia. Presented at: The 55 ASH® Annual Meeting and Exopsition. LA, USA, 7–10 December 2013 (Abstract 251).
  Google Scholar
• 18 Fowler NH, Advani RH, Sharman JP et al. The Bruton’s tyrosine kinase inhibitor ibrutinib (PCI-32765) is active and tolerated in relapsed follicular lymphoma. Presented at: The 55 ASH® Annual Meeting and Exopsition. GA, USA, 8–11 2012 (Abstract 156).
  Google Scholar
• 19 Byrd JC, O'Brien S, James DF. Ibrutinib in relapsed chronic lymphocytic leukemia. N. Engl. J. Med. 369(13), 1278–1279 (2013).
  Medline CASGoogle Scholar
• 20 Rushworth SA, Bowles KM, Barrera LN, Murray MY, Zaitseva L, MacEwan DJ. BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-kappaB. Cell. Signal. 25(1), 106–112 (2013).
  Medline CASGoogle Scholar
• 21 Rushworth SA, Murray MY, Zaitseva L, Bowles KM, MacEwan DJ. Identification of Bruton's tyrosine kinase as a therapeutic target in acute myeloid leukemia. Blood 123(8), 1229–1238 (2013).
  MedlineGoogle Scholar
• 22 Hallek M, Cheson BD, Catovsky D et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111(12), 5446–5456 (2008).
  Medline CASGoogle Scholar
• 23 Cheson BD, Byrd JC, Rai KR et al. Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia. J. Clin. Oncol. 30(23), 2820–2822 (2012).
  Medline CASGoogle Scholar
• 24 Chang B, Furman RR, Zapatka M et al. Use of tumor genomic profiling to reveal mechanisms of resistance to the BTK inhibitor ibrutinib in chronic lymphocytic leukemia (CLL). Presented at: ASCO Annual Meeting. IL, USA, 31 May–4 June 2013 (Abstract 7014).
  Google Scholar
• 25 Burger JA, Landau D, Hoellenriegel J et al. Clonal evolution in patients with chronic lymphocytic leukemia (CLL) developing resistance to BTK inhibition. Presented at: The 55th ASH® Annual Meeting and Exposition. LA, USA 7–10 December 2013 (Abstract 866
  Google Scholar
• 26 Burger JA, Keating MJ, Wierda WG et al. Ibrutinib in combination with rituximab (iR) is well tolerated and induces a high rate of durable remissions in patients with high-risk chronic lymphocytic leukemia (CLL): new, updated results of a Phase II trial in 40 patients. Presented at: The 55th ASH® Annual Meeting and Exposition. LA, USA 7–10 December 2013 (Abstract 675
  Google Scholar
• 27 Jaglowski SM, Jones JA, Flynn JM et al. A Phase Ib/II study evaluating activity and tolerability of BTK inhibitor PCI-32765 and ofatumumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and related diseases. Presented at: 2012 ASCO Annual Meeting. IL, USA, 1–5 June 2012 (Abstract 6508).
  Google Scholar
• 28 Kohrt H, Sagiv-Barfi I, Rafiq S et al. Ibrutinib (PCI-32765) antagonizes rituximab-dependent NK-cell mediated cytotoxicity. Presented at: The 55 ASH® Annual Meeting and Exopsition. LA, USA, 7–10 December 2013 (Abstract 373).
  Google Scholar
• 29 Bottcher S, Ritgen M, Fischer K et al. Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. J. Clin. Oncol. 30(9), 980–988 (2012).
  MedlineGoogle Scholar
• 30 Brown JR, Barrientos JC, Barr PM et al. Ibrutinib in combination with bendamustine and rituximab is active and tolerable in patients with relapsed/refractory CLL/SLL. Presented at: The 55 ASH® Annual Meeting and Exopsition. LA, USA, 7–10 December 2013 (Abstract 525).
  Google Scholar
• 31 A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma. www.clinicaltrials.gov/ct2/show/NCT01776840
  Google Scholar
• 32 Younes A, Flinn I, Berdeja J et al. Combining ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP): updated results from a Phase 1b study in treatment-naive patients with CD20-positive B-Cell non-Hodgkin's lymphoma (NHL). Presented at: The 55 ASH® Annual Meeting and Exopsition. LA, USA, 7–10 December 2013 (Abstract 852).
  Google Scholar
• 33 Liu J, Fitzgerald ME, Berndt MC, Jackson CW, Gartner TK. Bruton tyrosine kinase is essential for botrocetin/VWF-induced signaling and GPIb-dependent thrombus formation in vivo. Blood 108(8), 2596–2603 (2006).
  Medline CASGoogle Scholar